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Background: Local ablative therapies such as stereotactically guided single-dose radiotherapy or helical intensity-
modulated radiotherapy (tomotherapy) with high single-doses are successfully applied in many centers in patients
with liver metastasis not suitable for surgical resection. This study presents results from more than 10 years of
clinical experience and evaluates long-term outcome and efficacy of this therapeutic approach.
Patients and methods: From 1997 to 2009 a total of 138 intrahepatic tumors of 90 patients were irradiated with
single doses of 17 to 30 Gy (median dose 24 Gy). Median age of the patients was 64 years (range 31–89 years).
Most frequent underlying tumor histologies were colorectal adenocarcinoma (70 lesions) and breast cancer
(27 lesions). In 35 treatment sessions multiple targets were simultaneously irradiated (up to four lesions at once).
Local progression-free (PFS) and overall survival (OS) after treatment were investigated using uni- and multiple
survival regression models.
Results: Median overall survival of all patients was 24.3 months. Local PFS was 87%, 70% and 59% after 6, 12 and
18 months, respectively. Median time to local progression was 25.5 months. Patients with a single lesion and no
further metastases at time of RT had a favorable median PFS of 43.1 months according to the Kaplan-Meier
estimator. The type of tumor showed a statistical significant influence on local PFS, with a better prognosis for
breast cancer histology than for colorectal carcinoma in uni- and multiple regression analysis (p = 0.05). Multiple
regression analysis revealed no influence of planning target volume (PTV), patient age and radiation dose on local
PFS. Treatment was well tolerated with no severe adverse events.
Conclusion: This study confirms safety of SBRT in liver lesions, with 6- and 12 months local control of 87% and
70%. The dataset represents the clinical situation in a large oncology setting, with many competing treatment
options and heterogeneous patient characteristics.Introduction
Liver metastases frequently occur in patients with can-
cer, with the incidence varying depending on the under-
lying type of disease. The most frequent underlying
tumor is localized in the gastrointestinal tract, predom-
inantly colorectal cancer; in these patients approximately
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distribution, and reproduction in any mediumprimary diagnosis, and around 50% have been reported
to develop liver lesions within 5 years from initial diag-
nosis [1]. In the past, radiation therapy played only a
minor role in the treatment of liver metastases, due to
the low tolerance of the normal liver tissue to radiation
[2]. Radiation-induced side effects, namely RILD (Radi-
ation Induced Liver Disease) were expected and thus RT
was used only in rare cases. Therefore, surgery or other
locally ablative alternatives were preferred in these
patients.
In case of oligometastasis to the liver surgical resection
is still the standard treatment, and locally ablative treat-
ments are often held back and are applied in heavilytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient and treatment details
Total number of analyzed patients/lesions 90 patients/138 lesions
Gender
Male 47 patients, 75 lesions
Female 43 patients, 63 lesions
Age [y]
Median, range [years] 64 (31 – 89)
Radiation technique [number of lesions]
Single-dose (radiosurgery) 138
Stereotactic Body RT (SBRT) 126
Helical IMRT (tomotherapy) 12
Treatment in 1 session
One lesion 62
Two lesions 28
Three lesions 6*
Four lesions 1
RT Dose
Median, range [Gy] 24 (17 – 30)
Applied doses Number
17–20 Gy 43
21–25 Gy 60
26–30 Gy 35
Previous treatment Number of patients
Surgery 18
RFA 3
LITT 3
TACE 1
Other metastases at time of RT Number
None 53
History of metastases 48
Simultaneous metastases 37
Planning Target Volume (median, range) 62 ml (11 – 333 ml)
Liver volume 1483 ml (range 982–2647 ml)
*1 patient with three lesions included in 1 target volume.
RT radiotherapy, LM liver metastasis, RFA radiofrequency ablation, TACE
transcatheter arterial chemoembolization, LITT laser-induced thermotherapy.
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Considering the outcome of patients with liver metasta-
ses, outcome substantially depends on cancer histology:
In patients with colorectal carcinoma survival rates of
up to 64% five years after intervention can be achieved
after surgical resection [3]. A recent metaanalysis on sur-
gical resection of liver metastases derived from breast
cancer describes a median overall survival of 40 months
and a median 5-year survival rate of 40% in a selected
patient cohort [4]. However, in a substantial number of
patients, unfortunately, liver lesions are not amenable to
resection, or patients suffer from severe comorbidities or
present with reduced overall performance status; thus,
surgical intervention may not be possible in these pa-
tients [5,6].
Locally ablative treatments such as radiofrequency
ablation (RFA), percutaneous ethanol injection (PEI) or
transcatheter arterial chemoembolization (TACE) are
therefore widely accepted alternative treatment ap-
proaches with promising local control rates [7-9]. Never-
theless, minimal-invasive techniques still have major
limitations such as tumor size and localization, and the
individual tumor blood supply. In many cases, tumors
still recur after a few months [10].
Modern radiation techniques have modified the role of
radiation therapy in this clinical situation and have led to
an establishment of this treatment modality in liver cancer
patients. Thus, application of even high tumoricidal doses
can be applied safely and non-invasively by stereotac-
tic body radiotherapy (SBRT), intensity-modulated RT
(IMRT) or even particle beam therapy (PBT) [11-21].
Many reports over the last years have shown favourable
local control rates after radiosurgery or hypofractionated
RT in liver metastases or even small primary liver tumors
with an advantageous toxicity profile [22-29].
The present study reports long-term follow-up of a
mono-institutional experience including 90 patients with
138 hepatic tumors treated at our institution.
Patients and methods
Patients and treatment
From 1997 to 2009 one hundred thirty-eight intrahepatic
tumors from ninety patients were irradiated with total
doses of 17 to 30 Gy (median dose 24 Gy) using stereotactic
body radiotherapy (SBRT) or helical intensity-modulated
radiotherapy (tomotherapy). Generally, following our in-
stitutional guidelines, these patients are treated with
radiosurgical approaches. The decision on whether RT was
performed by SBRT or HT (helical tomotherapy) was made
according to current treatment capacities in our institution
and had no medical or dosimetric reasons.
Median age was 64 years (range 31–89 years). A total
of 126 lesions were irradiated using SBRT and 12 lesions
using tomotherapy. Applied single fraction doses variedfrom 17 to 30 Gy and in most treatments the following
doses were prescribed: 24 Gy (41 pts.), 20 Gy (37 pts.),
28 Gy (24 pts.) and 22 Gy (14 pts.) (Table 1).
In most cases dose was prescribed to the 80%-isodose
in case of single-dose RT. In some cases the applied dose
was prescribed to the dose maximum when appropriate,
depending on the size of the lesion, proximity to organs
at risk such as the intestines, or proximity to other radi-
ation treatment volumes. In 28 cases two lesions were ir-
radiated in one session, six patients received single-dose
RT to a PTV encompassing three different lesions and
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Six patients received more than one radiation course be-
cause of recurrent lesions during observation period.
Median irradiated planning target volume was 62 ml
(range 11–333 ml) and average normal liver volume was
1483 ml (range 982–2647 ml) (Table 1).
The most frequent primary tumor site was colorectal
adenocarcinoma (70 pts.), followed by breast cancer (27 pts.),
pancreatic adenocarcinoma (11 pts.) and ovarian cancer
(7 pts.) (Table 2).
Patient immobilization and treatment planning
Patients were immobilized as described previously
[22,30]. In brief, patients were immobilized using an in-
dividually shaped vacuum pillow and an abdominal com-
pression to reduce the liver movement. A contrast agent
enhanced CT scan and a 4D-CT series for quantifying
liver motion was acquired for treatment planning.
The extracranial stereotactic set-up has been devel-
oped at the German cancer research center (dkfz) and is
commercially available (Leibinger, Freiburg, Germany).
The patient is positioned in an individually shaped
vacuum pillow (Brandis Medizintechnik, Weinheim,
Germany). The intra-corporal movement of the liver was
reduced by epi-gastrical compression using a triangular
Plexiglas plate. Fixation of the plate is performed by two
bars, which are firmly attached to the metal arch. A
Siemens somatom plus 4 (Siemens, Erlangen, Germany)
was used for treatment planning. A spiral CT scan with
5 mm slice thickness and 500 mm field of view wasTable 2 Primary tumor sites
Primary tumor site Number of treated liver
metastases
TOTAL 138
Colorectal adenocarcinoma 70
Adenocarcinoma of the breast 27
Pancreatic adenocarcinoma 11
Ovarian cancer 7
Lung cancer 6
Gastric cancer 3
Sarcoma 2
Cholangiocarcinoma 2
Esophagus 2
Endometrium 2
Lymphoma 1
Renal Cell Cancer 1
Cervival cancer 1
Adenoid-cystic carcinoma 1
Anal Cancer 1performed which included the localization system. The
patients were advised to breathe normally during the
scanning time without taking deep breaths.
On the treatment day patients were repositioned in
the above mentioned setting using pen marks and an-
other control CT scan. Until the year 2003, CT imaging
was performed offline, and, if positioning was adequate,
patients were brought to the linear accelerator (LINAC)
using an individual shuttle system leaving the patient in
the vacuum bag/abdominal press fixation. In recent
years (2004–2009), LINACs (e.g. Siemens Artiste, Siemens
Healthcare, Erlangen, Germany) were equipped with
on-board imaging as, e.g. in case of tomotherapy, a
combination of the 6 MeV LINAC with CT imaging.
Target and OAR contouring was performed using Siemens
Dosimetrist and Oncologist software, and inverse treat-
ment planning was conducted applying the Hi-ART
Tomotherapy planning software (TomoTherapy Inc.,
Madison, WI, USA). Dose constraints for adjacent organs
at risk and the liver were used accroding to Emami et al.
and Dawson et al. [31,32].
Follow-up
Median follow-up was 21.7 months (range 1.6 –
151.8 months). Local failure patterns were determined
by follow-up clinical examination, radiographic imaging
including CT- and MRI scans as well as ultrasound.
Overall survival (OS) was calculated from the treatment
day on. Local Progression-free survival was determined
as the period between the treatment day and appearance
of any local recurrence; data was censored in case of
death without progression or last follow-up in patients
without progression. Univariate survival curves were
plotted based on the Kaplan-Meier method. In addition
to univariate analyses, multiple regression relying on a
proportional hazard (Cox) model was performed. Statis-
tical calculations were implemented using SAS version
9.2 (SAS Institute, Cary, NC, USA), and survival curves
were plotted using R 2.11.0 (www.rproject.org).
Results
Overall survival (OS)
The median OS for all patients was 24.3 months (95%-
CI 20.8 – 28.6 months), the corresponding survival
curves are represented in Figure 1. Relevant factors asso-
ciated with a poor prognosis according to univariate
analyses were the primary site of the tumor (HR = 2.56
for ‘other’ compared to colorectal tumors, global p =
0.002), the number of lesions (p < 0.001) and a late cal-
endar year (2001–2009) at diagnosis (HR = 1.52, p =
0.04). Multiple regression survival analysis consistently
pointed out to a poorer prognosis of patients with me-
tastases outside the liver at the time of RT or a history
of metastasis (HR = 2.64, p = 0.003), and also the number
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Figure 1 Kaplan-Meier overall survival curve for all patients.
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OS (p = 0.02). Patients with a primary tumor histology of
colorectal cancer had a better prognosis than other histol-
ogies (HR = 4.39, p = 0.0009).
Progression-free survival
The proportions of lesions without local progression
after 6, 12 and 18 months were 87.3%, 69.9% and 58.5%
respectively. The median time to local progression was
25.5 months for the entire patient group (Figure 2). The
number of metastases (one vs. multiple) that were in-
cluded in one or more PTVs or were irradiated simul-
taneously during one session showed no influence on
local control (p = 0.76). The type of tumor showed an in-
fluence on the local control of irradiated metastases, le-
sions from patients suffering from colorectal carcinoma
(‘crc’) showed a poorer control than those from patients
affected by breast cancer (‘bc’) in univariate and multiple0 1 2 3 4
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Figure 2 Local progression-free time (PFS) of lesions.regression analyses (multivariate HR for breast cancer
0.15, p = 0.05). The survival curve on Figure 3 suggest
that, after single-dose SBRT, lesions in patients with
metastasis from breast cancer show a slower local
progression.
The effects on progression of planning target volume
(PTV) (11–59 ml or 60–333 ml), patients’ age (31–59 or
60–89 years), primary tumor site (colorectal cancer,
breast cancer, other), number of metastases (singular vs.
multiple) and applied radiation dose (17–22 Gy, 23–
24 Gy, >25 Gy) did not reach statistical significance
according to multiple Cox regression. Patients with a
single lesion had a median PFS of 43.1 months according
to the Kaplan-Meier estimator, but survival differences
between patients with single lesions and those patients
with other lesions than the treated ones at time of RT
did not reach statistical significance according to uni-
and multiple regression models (univariate: p = 0.32,
multivariate: p = 0.41).
Toxicity
Overall tolerance of RT was high. Radiation side effects
were mild and included in some cases mild fever, nau-
sea, chills, loss of appetite and transient elevation of al-
kaline phosphatase. No Radiation-induced-liver disease
(RILD) was observed in the entire patient group.
Discussion
In the present work we report our long-term follow up
of highly conformal radiation therapy in patients with
liver metastases delivered as radiosurgery. In this cohort
of 90 patients with 138 metastatic lesions, local control
was nearly 90% after six months. The main underlying
tumor type was colorectal cancer, followed by breast0 1 2 3 4
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Figure 3 Local progression-free survival of patients with
metastases from colorectal carcinoma (CRC) and
adenocarcinoma of the breast (BC). Kaplan-Meier curve of PFS
according to primary tumor site.
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24.3 months, and prognostic factors included primary
tumor histology. In our analysis of this patient group
with a wide variety of different underlying primary tu-
mors and different systemic and local pre-treatments,
local control rates within the range of published data
(Table 3) can be achieved with single fraction RT even
in case of multiple target lesions.
In general, the development of SBRT or other tech-
niques to deliver precisely high local doses have changed
the paradigm for radiation therapy in the multimodal
treatment of liver metastases. Radiation tolerance of liver
normal tissue is limited in contrast to the high local
doses required for long-term local control of metastatic
lesions. The dose-limiting toxicity of the whole liver is
RILD, which in the early days was named radiation hepa-
titis [33]. It is characterized by a rise in liver enzymes,
namely alkaline phosphatase, and ascites; histopathologic-
ally, venous occlusion is the most predominant change in
pathological specimens [34].
Respecting individual target volumes and dosing
schemes, toxicity rates can be minimized, even for larger
volumes. In contrast to primary liver cancer, liver metasta-
ses most commonly occur in non-cirrhotic livers, and the
most predominant toxicity to radiation will be RILD; how-
ever, adhering to established dose constraints of normal
liver tissue, i.e. keeping below 30 Gy median liver dose in
conventional fractionation [31] or application of less than
15 Gy to 700 ml of healthy liver tissue, this may be se-
curely avoided. Most of the studies report mild adverse
events such as transient elevation of alkaline phosphatase
or fatigue symptoms, toxicity grade III or higher (CTCAE)
is very uncommon and occurs only when high doses are
applied to the small bowel or to large volumes of the liver
[35]. However in our analysis no higher grade toxicities
were recorded, especially no clinically apparent RILD.
Nevertheless a major weakness of this work remains the
documentation of detailled toxicity aspects according to
the Common Toxicity Criteria for Adverse Events
(CTCAE) because of the retrospective nature of the study.
The available medical records and documents did not
point out to higher grade of clinically relevant adverse
events, e. g. gastro-intestinal ulceration. Therefore we
refer to published reports on comparable radiosurgery
treatment protocols where mostly mild toxicities are ob-
served and higher grad toxicities are surely very rare
events (see Table 3).
Median overall survival of patients with untreated liver
metastasis differs among histologies of the primary
tumor between 5 and 19 months [36,37]. After surgical
resection a five-year OS of 64% can be achieved [3]. Pa-
tients should only undergo resection if clear resection
margins can be achieved (R0-resection), because positive
margins (including R1- and R2-resections) are associatedwith a poor five-year OS of 0% in many case series
[38,39]. While surgery is the mainstay of treatments,
substantial numbers of patients are not amenable for
surgical resection, often for underlying medical condi-
tions [5,6]. Therefore a current need for local ablative
treatment options in liver metastasis is evident. With the
advancing techniques of SBRT and other elaborate mo-
dalities allowing for precise local high dose deposition,
several institutions have treated a large number of pa-
tients with liver metastases, either applying radiosurgery
or hypofractionated regimens (Table 3). Survival of pa-
tients in our analysis is relatively good and in the range
of the above mentioned group of patients undergoing
surgery. Median OS was 24.3 months and depending on
the prognostic subgroup (breast cancer histology, no fur-
ther metastases at time of RT) median local PFS is even
higher.
Recently a phase-I clinical trial examining a dose escal-
ation with single-fraction SBRT from initially 18 to
30 Gy in 19 patients with hepatic metastases has shown
efficacy without reporting dose-limiting toxicity [21].
Risk for local failure 12 months after treatment was 23%.
Table 3 provides a summary of the largest studies on
SBRT of liver metastases, including single-fraction RT as
well as the more commonly used 3–5 fraction protocols.
Overall, local control ranges between 70 and 95% at one
year, depending on the series; however, only few studies
have been conducted using a formal dose-escalation
part. Rusthoven and colleagues performed a multicentric
phase I/II clinical trial starting with 36 Gy at 3 fractions,
and dose was escalated in 6 Gy increments up to a de-
fined maximum of 60 Gy [11]. Tumor volume was a
strong predictor for local control, with smaller lesions
showing a longer tumor control. Colleagues from the
University of Texas Southwestern reported on a Phase I
study starting with 30 Gy in 3 fractions up to 60 Gy in 5
fractions [28]. An argument for the five-fraction scheme
was the potential to treat lesions in close vicinity to
periportal biliary structures avoiding radiation-induced
toxicity with lower single doses. A third dose-escalation
study was published by Goodman et al. and was phase I
dose-escalation single-fraction trial including not only
patients with liver metastases, but also with intrahepatic
cholangiocarcinoma [21]. Dose escalation was conducted
in 4 Gy treatment groups from 18–30 Gy, in a single
fraction. Also in this study, no dose limiting side effects
were observed. A recent mono-institutional analysis of
heavily local and systemic pre-treated patients with liver
tumors undergoing cyber knife ®-based RT showed the
feasibility and efficacy of 3–5 fraction regimens with
doses of BED ≥ 79.2 Gy10 = 66 Gy EQD2 [40]. In this
setup remarkable LC rates of up to 74% after 2 years can
achieved with doses of BED ≥ 100 Gy10. But there are
also some reports indicating higher local control rates of
Table 3 Literature overview
Author Year Primary
tumour
Number of
patients
Number of
fractions
Overall dose Local control Details
Herfarth et al. [14] 2001 Mets and
PLC
56 1 14 – 26 Gy 67% after 18 months
Wulf et al. [15] 2001 Mets and
PLC
56 3 27 pts. 3 x 10 Gy
1 pt. 4 x 7 Gy
61% after 2 years PLT: 100% after
median f/u 15 mo.
19 pts. 3 x 12-12
.5 Gy
1 pt. 1 x 26 Gy
Schefter et al. [16] 2005 Mets 18 3 9 Pts.: 36 Gy Not reported Phase-I study
9 Pts.: 60 Gy
Hoyer et al. [17] 2006 Mets 44 3 45 Not reported Phase-II study,
Liver-specific data
not reported
Kavanagh et al.
[18]
2006 Mets 36 3 60 Gy 93% after 18 months Phase-I/II study
Mendez-Romero
et al. [19]
2006 Mets and
PLC
45 3 37.5 Gy 82% after 2 years Phase-I/II study
(also 5 x 5 Gy
or 3 x 10 Gy)
Katz et al. [27] 2007 Mets 174 7 – 20 30 – 55 Gy 57% after 20 months Lesion diameter
ranged from
0.6 – 12.2 cmmedian 48 Gy
Rusthoven et al.
[11]
2009 Mets 63 3 36 – 60 Gy 95%, 92% after 1 and 2 years Phase-I/II study
Lee et al. [12] 2009 Mets 68 6 27.7 – 60 Gy 71% after 1 year Phase-I study
median 41.8 Gy
Van der Pool
et al. [20]
2010 Mets 31 3 12.5 Gy (n = 29) 74% after 2 years Grade III toxicities
were hepatic
15 Gy (n = 2)
Goodman et al.
[21]
2010 Mets and
PLC
40 1 18 – 30 Gy 77% after 1 year Phase-I study
Rule et al. [28] 2011 Mets 37 3 or 5 30 – 60 Gy 56%, 89%,100% for 30, 50 and 60-
Gy after 2 years
Phase-I study
(30 Gy/3 fx, 50 and
60 Gy in 5 fx)
Chang et al. [29] 2011 Mets 65 1-6 22–60 Gy, median
42 Gy
67%, 55% after 1 and 2 years
Vautravers-Dewas
et al. [41]
2011 Mets 42 3-4 40 Gy/4 fx,
45 Gy/3 fx
86% after 2 years
Lanciano et al.
[40]
2012 Mets and
PLC
30 3 or 5 79.2–180 Gy10 75%, 57% with BED10 >100 Gy
after 1 and 2 years
(66–150 Gy BED2)
This study 2013 Mets 138 1 10-30 Gy, median
24 Gy
87%, 69% and 59% after 6, 12
and 18 months
HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 ×12.5 Gy. Patients with HCC ≥ 4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy.
Gy Gray, CRC colorectal carcinoma, mets metastases, Pts. Patients, Pt. patient, DLT Dose-limiting toxicity, PLC Primary Liver cancer, fx fractions, LC Local Control.
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3-fraction SBRT, when doses of 45–48 Gy (BED) are
applied [29,41].
As a summary of available studies it be may be con-
cluded that SBRT for liver metastasis leads to a 1- and
2-year local control of approximately 60-100% depend-
ing on patient group and fractionation scheme (recently
reviewed by [35]). With regard to these data, our data
reported in the present manuscript fit well in the rangeof reported data, confirming 12- and 18-months PFS
rates of 70% and 59%; however, in our group, patients
presented with heterogeneous primary tumors, pretrea-
tments, comorbidities and lesion characteristics. In
comparison to many prospective studies, this dataset
represents more a “real-life” scenario reflecting the clin-
ical situation in a large oncology setting, with many
competing treatment options. Additionally, the data con-
firms safety of the method in this group of patients, also
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while reporting these real-life data, limitations of such
an analysis must be kept in mind, such as some patients
being lost-to-follow-up, or some data limitations due to
the retrospective nature of the report.
The most analysed patient group of SBRT treated liver
metastasis are patients with metastases derived from
colorectal cancer. In several studies outcome of this pa-
tient group was relatively worse compared to other pri-
mary tumors which also can be confirmed by our
analysis with 1-year local control rates of 67% for CRC
compared to 90% for breast cancer patients [12,42]. One
possible explanation of this observation may be the fact
that CRC patients are often heavily pre-treated with sev-
eral chemotherapy regimens and may therefore develop
a cross resistance to ionizing radiation; moreover, due to
the prior chemotherapeutic regimens patients are re-
ferred at a later stage of their disease, which might also
explain the reduced outcome in CRC patients.
With increasing lesion volume safety concern with sin-
gle fraction treatments become evident. Thus, multi-
fraction schedules using 3–6 fractions may provide a
better risk-benefit profile. However median lesion size of
irradiated metastases certainly varies among different
studies. While some authors report tumor size with the
longest diameter or volume, others analysed the plan-
ning target volume, as we did in our study. Notably
some authors found a dose-volume relationship [11,12]
whereas our analysis failed to support a dependency of
PTV and tumor response. Recent reports of other
groups also failed to show a dependency between size
and LC [29,40,41].
Future studies in this field will elucidate the benefit of
more (tumor-) adaptive radiotherapeutic procedures.
Using highly conformal image-guided radiotherapy
intrahepatic tumors can be irradiated with smaller safety
margins, thus normal liver tissue can be prevented from
radiation damage. For this purpose, e.g. fiducial markers
are implanted in proximity of the target lesion and can
be visualized by computed tomography or x-ray images
as a tumor surrogate to assure its correct position dur-
ing treatment. New technologies such as gating and
tracking of target lesions depend on the breathing phase
and are correlated with the dose application [43-45].
Finally many retrospective studies and phase-I/-II clin-
ical trials on SBRT have shown a high local control rate
of intrahepatic metastases while avoiding severe therapy-
related complications in patients not suitable for resec-
tion. Best results were achieved with hypofractionated
regimens and overall dose above 40 Gy in selected pa-
tient groups. The role of radiation therapy for the treat-
ment of patients with liver metastases should therefore
be re-defined and kept in mind in interdisciplinary treat-
ment decisions. Further clinical evaluation, preferentiallyin randomized settings comparing to surgery of other lo-
cally ablative techniques, will further elucidate the full
potential of SBRT in patients with liver metastases, es-
pecially in the subgroup of oligometastasized patients.
Nevertheless prospective randomized clinical trials (RCT)
comparing different local ablative therapies, e.g. TACE/
RFA and SBRT, are still lacking. According to this issue
most recently Hoyer et al. initiated a multi-institutional
RCT comparing RFA and SBRT for hepatic oligometas-
tasis (1–4) (RAS01-Trial, NCT01233544) [35].
Conclusion
Our analysis of a large retrospectively evaluated mono-
institutional patient group who was treated with single-dose
SBRT for liver metastases clearly shows a good local control
rate. Many of these patients had more than one intrahepatic
lesion or suffered from multiple metastases during treat-
ment. Moreover there were different underlying primary tu-
mors with impact on local control. In summary the analysis
provides further evidence of the efficacy of highly conformal
radiation, serving a basis for additionally radiotherapeutic
improvements or a rationale for randomized trials with
other locally ablative treatments or surgery. The dataset sup-
ports the use of SBRT in liver lesions, also in heavily pre-
treated patients or with larger lesions, with a convincing
safety profile and sufficient lesion control probability.
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